MiNK Therapeutics/$INKT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Ticker
$INKT
Sector
Primary listing
Employees
23
Headquarters
Website
INKT Metrics
BasicAdvanced
$52M
-
-$3.02
0.33
-
Price and volume
Market cap
$52M
Beta
0.33
52-week high
$76.00
52-week low
$4.56
Average daily volume
21K
Financial strength
Current ratio
1.082
Quick ratio
1.063
Total debt to equity
-42.369
Profitability
EBITDA (TTM)
-12.242
Management effectiveness
Return on assets (TTM)
-69.61%
Return on equity (TTM)
79.54%
Valuation
Price to book
-3.8
Price to tangible book (TTM)
-3.8
Price to free cash flow (TTM)
-8.178
Free cash flow yield (TTM)
-12.23%
Free cash flow per share (TTM)
-1.365
Growth
Earnings per share change (TTM)
-20.01%
3-year earnings per share growth (CAGR)
-27.25%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MiNK Therapeutics stock?
MiNK Therapeutics (INKT) has a market cap of $52M as of November 27, 2025.
What is the P/E ratio for MiNK Therapeutics stock?
The price to earnings (P/E) ratio for MiNK Therapeutics (INKT) stock is 0 as of November 27, 2025.
Does MiNK Therapeutics stock pay dividends?
No, MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders as of November 27, 2025.
When is the next MiNK Therapeutics dividend payment date?
MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders.
What is the beta indicator for MiNK Therapeutics?
MiNK Therapeutics (INKT) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.